Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates

March 23rd 2020


Bone Therapeutics today announces it has received regulatory approvals for its Clinical Trial Applications for the next studies of both of its lead candidates. These two studies are the pivotal JTA-004 Phase III clinical study targeting osteoarthritic knee pain and the Phase IIb study of its allogeneic cell therapy product, ALLOB, in patients with difficult tibial fractures. The JTA-004 trial has been approved by regulatory authorities in Denmark, and the ALLOB by Belgian regulatory authorities.  Please discover the press release here.